New Jersey Senate Bill 3098 would require health insurance plans to cover biomarker testing for the diagnosis, treatment, and management of a patient's disease.
Pfizer will discuss the data on its CDK4/6 inhibitor plus anti-HER2 and endocrine therapy with regulators, hoping it will become a new standard option.
A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...
Researchers founded Rarity PBC as a public benefit corporation that will license the IP and develop operations to potentially ...
SAN ANTONIO – In a global study involving more than 5,000 women, risk-reducing surgeries significantly improved survival and ...
The variant, present in the NFKB1 gene and common in the Aymara community, could help guide treatment decisions, researchers ...
NEW YORK – The availability of AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for treating HER2-low breast ...
Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...
In particular, patients who had fewer than 10 annual vaso-occlusive events before the gene therapy were more likely to have ...
Lymphoma patients better tolerated the CAR T-cell therapy manufactured on site at the Sheba Medical Center than they did the ...
Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.
SAN DIEGO – Gilead Sciences and Arcellx's autologous B-cell maturation antigen (BCMA)-directed CAR T-cell therapy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback